{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:27:05Z","timestamp":1781270825993,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the University of Wisconsin\u2013 Madison and the National Institutes of Health","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472018, 82171970"],"award-info":[{"award-number":["82472018, 82171970"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20240484725"],"award-info":[{"award-number":["20240484725"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2024YFE0113500"],"award-info":[{"award-number":["2024YFE0113500"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z221100007422027"],"award-info":[{"award-number":["Z221100007422027"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2023IR17, 2024IR07"],"award-info":[{"award-number":["2023IR17, 2024IR07"]}]},{"name":"Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital","award":["2024CX18"],"award-info":[{"award-number":["2024CX18"]}]},{"name":"the Scientific and technological project in Henan Province","award":["242102311026"],"award-info":[{"award-number":["242102311026"]}]},{"name":"Henan Medical Science and Technology Research Program Joint Construction Project","award":["LHGJ20220409"],"award-info":[{"award-number":["LHGJ20220409"]}]},{"name":"The Henan Association for Science and Technology Youth Talent Support Program","award":["2023HYTP039"],"award-info":[{"award-number":["2023HYTP039"]}]},{"name":"The Key Research Project in Henan Universities","award":["23A320059"],"award-info":[{"award-number":["23A320059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00259-025-07167-5","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T03:44:25Z","timestamp":1740455065000},"page":"3223-3237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [64Cu]Cu-NOTA-Trodelvy-F(ab\u2019)2"],"prefix":"10.1007","volume":"52","author":[{"given":"Wenpeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Mixdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4641-0833","authenticated-orcid":false,"given":"Weibo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"7167_CR1","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee Y-G, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545.","journal-title":"Biochem Pharmacol"},{"key":"7167_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136\u201345.","journal-title":"Semin Cancer Biol"},{"key":"7167_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"7167_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acs.bioconjchem.0c00649","volume":"32","author":"C Li","year":"2021","unstructured":"Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, et al. ImmunoPET of CD146 in Orthotopic and metastatic breast Cancer models. Bioconjug Chem. 2021;32:1306\u201314.","journal-title":"Bioconjug Chem"},{"key":"7167_CR5","doi-asserted-by":"publisher","first-page":"1332489","DOI":"10.3389\/fimmu.2023.1332489","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.","journal-title":"Front Immunol"},{"key":"7167_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.21037\/atm-22-5976","volume":"10","author":"Y Wen","year":"2022","unstructured":"Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403.","journal-title":"Ann Transl Med"},{"key":"7167_CR7","doi-asserted-by":"crossref","unstructured":"De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024.","DOI":"10.1007\/s12282-024-01565-7"},{"key":"7167_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-negative breast Cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"7167_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00259-023-06454-3","volume":"51","author":"W Huang","year":"2024","unstructured":"Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7167_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","volume":"20","author":"F Shao","year":"2022","unstructured":"Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, et al. Nectin-4-targeted immunoSPECT\/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnol. 2022;20:243.","journal-title":"J Nanobiotechnol"},{"key":"7167_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2967\/jnumed.120.246595","volume":"62","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive evaluation of CD20 expression using 64Cu-Labeled F(ab\u2019)2 fragments of Obinutuzumab in Lymphoma. J Nucl Med. 2021;62:372\u20138.","journal-title":"J Nucl Med"},{"key":"7167_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2174\/1389201022666210810104226","volume":"23","author":"S Ghani","year":"2022","unstructured":"Ghani S, Deravi N, Pirzadeh M, Rafiee B, Gatabi ZR, Bandehpour M, et al. Antibody fragment and targeted colorectal Cancer therapy: A global systematic review. Curr Pharm Biotechnol. 2022;23:1061\u201371.","journal-title":"Curr Pharm Biotechnol"},{"key":"7167_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.62347\/HUQD8000","volume":"14","author":"S Malih","year":"2024","unstructured":"Malih S, Lin W, Tang Z, DeLuca MC, Engle JW, Alirezapour B, et al. Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab. Am J Nucl Med Mol Imaging. 2024;14:31\u201340.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"7167_CR14","doi-asserted-by":"crossref","unstructured":"Huang W, Wang T, Qiu Y, Li C, Chen B, Song L et al. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. Eur J Nucl Med Mol Imaging. 2024.","DOI":"10.1007\/s00259-024-07036-7"},{"key":"7167_CR15","doi-asserted-by":"crossref","unstructured":"Chen Z, Yang Q, Song L, Qiu Y, Wang T, Wu S et al. Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Mol Pharm. 2024.","DOI":"10.1021\/acs.molpharmaceut.4c00084"},{"key":"7167_CR16","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00259-023-06575-9","volume":"51","author":"Q Yang","year":"2024","unstructured":"Yang Q, Chen Z, Qiu Y, Huang W, Wang T, Song L, et al. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:1246\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7167_CR17","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med"},{"key":"7167_CR18","doi-asserted-by":"crossref","unstructured":"Huang W, Li L, Zhou Y, Yang Q, Mixdorf JC, Barnhart TE et al. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07106-4"},{"key":"7167_CR19","first-page":"1","volume":"37","author":"The 2007 Recommendations of the International Commission on Radiological Protection","year":"2007","unstructured":"The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1\u2013332.","journal-title":"Ann ICRP"},{"key":"7167_CR20","first-page":"1671","volume":"12","author":"P Jabbarzadeh Kaboli","year":"2022","unstructured":"Jabbarzadeh Kaboli P, Shabani S, Sharma S, Partovi Nasr M, Yamaguchi H, Hung M-C. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12:1671\u201385.","journal-title":"Am J Cancer Res"},{"key":"7167_CR21","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-negative breast Cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"7167_CR22","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1111\/jcmm.13547","volume":"22","author":"X-X He","year":"2018","unstructured":"He X-X, Du S, Gao S-Q, Chen J-Y, Cao R-J, Xing Z-K, et al. Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells. J Cell Mol Med. 2018;22:3259\u201363.","journal-title":"J Cell Mol Med"},{"key":"7167_CR23","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1021\/acs.bioconjchem.9b00235","volume":"30","author":"S Hirasawa","year":"2019","unstructured":"Hirasawa S, Kitahara Y, Okamatsu Y, Fujii T, Nakayama A, Ueno S, et al. Facile and efficient Chemoenzymatic Semisynthesis of Fc-Fusion compounds for Half-Life Extension of Pharmaceutical Components. Bioconjug Chem. 2019;30:2323\u201331.","journal-title":"Bioconjug Chem"},{"key":"7167_CR24","doi-asserted-by":"publisher","first-page":"eado2461","DOI":"10.1126\/scitranslmed.ado2461","volume":"16","author":"W Chen","year":"2024","unstructured":"Chen W, Zhang Y, Zhang L, Luo X, Yang X, Zhu Y, et al. Intraoperative evaluation of tumor margins using a TROP2 near-infrared imaging probe to enable human breast-conserving surgery. Sci Transl Med. 2024;16:eado2461.","journal-title":"Sci Transl Med"},{"key":"7167_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41181-023-00235-x","volume":"9","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li T, Zhang X, Jing H, Li F, Huo L. Preclinical evaluation of the theranostic potential of 89Zr\/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI Radiopharm Chem. 2024;9:5.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"7167_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of 64Cu\/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7167_CR27","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/acs.molpharmaceut.3c00041","volume":"20","author":"D Shi","year":"2023","unstructured":"Shi D, Xu Z, Cheng Y, Lin Q, Si Z, Fu W, et al. 124I-Labeled Immuno-PET Targeting hTREM2 for the diagnosis of gastric carcinoma. Mol Pharm. 2023;20:2235\u201344.","journal-title":"Mol Pharm"},{"key":"7167_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2967\/jnumed.114.149690","volume":"56","author":"CT Mendler","year":"2015","unstructured":"Mendler CT, Gehring T, Wester H-J, Schwaiger M, Skerra A. 89Zr-Labeled Versus 124I-Labeled fabR2 FaboptimizediplasmaPhalfalifef-Lifhighrcontrastntrast Tumor Iminivivon Vivo. J Nucl Med. 2015;56:1112\u20138.","journal-title":"J Nucl Med"},{"key":"7167_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1021\/bc4004926","volume":"25","author":"S L\u00fctje","year":"2014","unstructured":"L\u00fctje S, Franssen GM, Sharkey RM, Laverman P, Rossi EA, Goldenberg DM, et al. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors. Bioconjug Chem. 2014;25:335\u201341.","journal-title":"Bioconjug Chem"},{"key":"7167_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.7150\/thno.9425","volume":"4","author":"NS Turker","year":"2014","unstructured":"Turker NS, Heidari P, Kucherlapati R, Kucherlapati M, Mahmood U. An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis. Theranostics. 2014;4:893\u2013903.","journal-title":"Theranostics"},{"key":"7167_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/jlcr.3803","volume":"62","author":"SK Suman","year":"2019","unstructured":"Suman SK, Kameswaran M, Pandey U, Sarma HD, Dash A. Preparation and preliminary bioevaluation studies of 68 Ga-NOTA-rituximab fragments as radioimmunoscintigraphic agents for non-hodgkin lymphoma. J Label Comp Radiopharm. 2019;62:850\u20139.","journal-title":"J Label Comp Radiopharm"},{"key":"7167_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2011.10.017","volume":"315","author":"S Kaur","year":"2012","unstructured":"Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012;315:97\u2013111.","journal-title":"Cancer Lett"},{"key":"7167_CR33","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861\u201371.","journal-title":"Mol Cancer Ther"},{"key":"7167_CR34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2967\/jnumed.109.073189","volume":"51","author":"BAW Hoeben","year":"2010","unstructured":"Hoeben BAW, Kaanders JHAM, Franssen GM, Troost EGC, Rijken PFJW, Oosterwijk E, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab\u2019)2 in head and neck tumors. J Nucl Med. 2010;51:1076\u201383.","journal-title":"J Nucl Med"},{"key":"7167_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11307-019-01386-7","volume":"22","author":"KA Zettlitz","year":"2020","unstructured":"Zettlitz KA, Tsai W-TK, Knowles SM, Salazar FB, Kobayashi N, Reiter RE, et al. [89Zr]A2cDb Immuno-PET of prostate Cancer in a human prostate stem cell Antigen knock-in (hPSCA KI) Syngeneic Model. Mol Imaging Biol. 2020;22:367\u201376.","journal-title":"Mol Imaging Biol"},{"key":"7167_CR36","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2967\/jnumed.115.159145","volume":"56","author":"SMJ van Duijnhoven","year":"2015","unstructured":"van Duijnhoven SMJ, Rossin R, van den Bosch SM, Wheatcroft MP, Hudson PJ, Robillard MS. Diabody Pretargeting with click Chemistry in vivo. J Nucl Med. 2015;56:1422\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07167-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07167-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:52:16Z","timestamp":1751435536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07167-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7167"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07167-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants (Clinical trial number: not applicable).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Weibo Cai declares conflict of interest with the following corporations: Portrai, Inc., rTR Technovation Corporation, Four Health Global Pharmaceuticals Inc., and POP Biotechnologies, Inc. Weibo Cai is Associate Editor of European Journal of Nuclear Medicine and Molecular Imaging. All other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}